keyword
MENU ▼
Read by QxMD icon Read
search

Parkinson's dementia outcome

keyword
https://www.readbyqxmd.com/read/29764386/parkinson-s-disease-diagnostic-observations-paddo-study-rationale-and-design-of-a-prospective-cohort-study-for-early-differentiation-of-parkinsonism
#1
Anouke van Rumund, Marjolein B Aerts, Rianne A J Esselink, Frederick J A Meijer, Marcel M Verbeek, Bastiaan R Bloem
BACKGROUND: Differentiation of Parkinson's disease (PD) from the various types of atypical parkinsonism (AP) such as multiple system atrophy (MSA), progressive supranuclear palsy (PSP), dementia with Lewy bodies (DLB), corticobasal syndrome (CBS) and vascular parkinsonism (VP), can be challenging, especially early in the disease course when symptoms overlap. A major unmet need in the diagnostic workup of these disorders is a diagnostic tool that differentiates the various disorders, preferably in the earliest disease stages when the clinical presentation is similar...
May 16, 2018: BMC Neurology
https://www.readbyqxmd.com/read/29699914/risk-factors-for-non-motor-symptoms-in-parkinson-s-disease
#2
REVIEW
Johan Marinus, Kangdi Zhu, Connie Marras, Dag Aarsland, Jacobus J van Hilten
Non-motor symptoms (NMS) of Parkinson's disease can be predominant as the disease advances, thereby constituting a major source of disease burden for patients and caregivers. However, current understanding of NMS is incomplete, particularly as a result of the absence of standardisation of outcome definitions and the heterogeneity of the risk factors that are assessed. The best data on risk factors for NMS in Parkinson's disease come from longitudinal studies, with the strongest evidence identifying factors for cognitive impairment and dementia, hallucinations, depression, apathy, excessive daytime sleepiness, insomnia, and impulse-control disorders...
April 23, 2018: Lancet Neurology
https://www.readbyqxmd.com/read/29681636/parkinsonism-as-presenting-symptom-of-primary-hyperparathyroidism-improvement-after-surgery
#3
Delia Luján-Martínez, Ángela Sánchez-Cifuentes, Emilio Peña-Ros, Antonio Albarracín-Marín-Blázquez, Mari Fe Candel-Arenas
Introduction: Hypercalcemia can cause different neurological disorders, depending on the calcium level. We report an exceptional case of primary hyperparathyroidism presenting as neurological alteration and it has favourable outcome after parathyroidectomy. Case report: A 74-year-old woman presented with progressive cognitive deterioration and impaired motor function. The complementary tests showed hypercalcemia due to a parathyroid adenoma. Parathyroidectomy was performed with symptomatic improvement...
2018: Cirugia y Cirujanos
https://www.readbyqxmd.com/read/29663553/rapid-evidence-assessment-of-approaches-to-community-neurological-nursing-care-for-people-with-neurological-conditions-post-discharge-from-acute-care-hospital
#4
REVIEW
Judith Dianne Pugh, Kathleen McCoy, Anne M Williams, Brenda Bentley, Leanne Monterosso
Neurological conditions represent leading causes of non-fatal burden of disease that will consume a large proportion of projected healthcare expenditure. Inconsistent access to integrated healthcare and other services for people with long-term neurological conditions stresses acute care services. The purpose of this rapid evidence assessment, conducted February-June 2016, was to review the evidence supporting community neurological nursing approaches for patients with neurological conditions post-discharge from acute care hospitals...
April 16, 2018: Health & Social Care in the Community
https://www.readbyqxmd.com/read/29662465/the-length-of-snca-rep1-microsatellite-may-influence-cognitive-evolution-in-parkinson-s-disease
#5
Lucia Corrado, Fabiola De Marchi, Sara Tunesi, Gaia Donata Oggioni, Miryam Carecchio, Luca Magistrelli, Silvana Tesei, Giulio Riboldazzi, Alessio Di Fonzo, Clarissa Locci, Ilaria Trezzi, Roberta Zangaglia, Cristina Cereda, Sandra D'Alfonso, Corrado Magnani, Giacomo P Comi, Giorgio Bono, Claudio Pacchetti, Roberto Cantello, Stefano Goldwurm, Cristoforo Comi
Background: Alpha-synuclein is a constituent of Lewy bodies and mutations of its gene cause familial Parkinson's disease (PD). A previous study showed that a variant of the alpha-synuclein gene ( SNCA ), namely the 263 bp allele of Rep1 was associated with faster motor progression in PD. On the contrary, a recent report failed to detect a detrimental effect of Rep1 263 on both motor and cognitive outcomes in PD. Aim of this study was to evaluate the influence of the Rep1 variants on disease progression in PD patients...
2018: Frontiers in Neurology
https://www.readbyqxmd.com/read/29624752/biomarkers-for-cognitive-impairment-in-lewy-body-disorders-status-and-relevance-for-clinical-trials
#6
REVIEW
Andrew Siderowf, Dag Aarsland, Brit Mollenhauer, Jennifer G Goldman, Bernard Ravina
Biomarkers have the potential to improve diagnosis and prognosis, and guide clinical treatment decisions. In research, biomarkers can be used for patient selection and as outcome measures in clinical trials. A range of biochemical and imaging biomarkers are relevant to patients with Lewy body disorders, including PD, PD dementia, and dementia with Lewy bodies. Dopaminergic imaging is used for differential diagnosis of parkinsonian disorders versus tremor disorders without dopamingeric deficits, and also to differentiate dementia with Lewy bodies from Alzheimer's disease...
April 2018: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/29600247/the-effects-of-combinations-of-cognitive-impairment-and-pre-frailty-on-adverse-outcomes-from-a-prospective-community-based-cohort-study-of-older-chinese-people
#7
Ruby Yu, John E Morley, Timothy Kwok, Jason Leung, Osbert Cheung, Jean Woo
Objectives: To examine how various combinations of cognitive impairment (overall performance and specific domains) and pre-frailty predict risks of adverse outcomes; and to determine whether cognitive frailty may be defined as the combination of cognitive impairment and the presence of pre-frailty. Design: Community-based cohort study. Participants: Chinese men and women ( n  = 3,491) aged 65+ without dementia, Parkinson's disease and/or frailty at baseline...
2018: Frontiers in Medicine
https://www.readbyqxmd.com/read/29599930/does-antipsychotic-drug-use-increase-the-risk-of-long-term-mortality-a-systematic-review-and-meta-analysis-of-observational-studies
#8
Chunsong Yang, Zilong Hao, Jinhui Tian, Wei Zhang, Wenting Li, Ling-Li Zhang, Fujian Song
Antipsychotics (AP) are widely used to treat schizophrenia and other psychiatric disorders. However, the association between the AP use and mortality risk is controversial. We searched PubMed, EMBASE, MEDLINE, PsycINFO, CINAHL, the Cochrane Library and four Chinese databases from inception to June 2016. All observational cohort or case-control studies reporting data on mortality outcomes in individuals exposed to AP drugs were included. This systematic review included 68 studies involving 4,812,370 participants...
March 13, 2018: Oncotarget
https://www.readbyqxmd.com/read/29558564/systems-approaches-to-optimizing-deep-brain-stimulation-therapies-in-parkinson-s-disease
#9
REVIEW
Sabato Santaniello, John T Gale, Sridevi V Sarma
Over the last 30 years, deep brain stimulation (DBS) has been used to treat chronic neurological diseases like dystonia, obsessive-compulsive disorders, essential tremor, Parkinson's disease, and more recently, dementias, depression, cognitive disorders, and epilepsy. Despite its wide use, DBS presents numerous challenges for both clinicians and engineers. One challenge is the design of novel, more efficient DBS therapies, which are hampered by the lack of complete understanding about the cellular mechanisms of therapeutic DBS...
March 20, 2018: Wiley Interdisciplinary Reviews. Systems Biology and Medicine
https://www.readbyqxmd.com/read/29543342/initial-cognitive-changes-in-parkinson-s-disease
#10
REVIEW
Daniel Weintraub, Alexander I Tröster, Connie Marras, Glenn Stebbins
The focus on cognitive impairment in neurodegenerative diseases, including PD, is shifting from the dementia stage to earlier stages of impairment, including mild cognitive impairment. This shift is driven primarily by the desire to improve long-term outcomes by delivering therapeutic interventions earlier in the clinical course, even presymptomatically in those at highest risk, and at the initial stage in the pathophysiological cascade that underpins common dementia syndromes. This article focuses on key findings and challenges in studying earliest stages of cognitive decline in PD, including a detailed examination of neuropsychological testing, cognitive performance in early and prodromal PD, epidemiological research for PD mild cognitive impairment to date, and expert recommendations for assessment...
March 15, 2018: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/29537978/a-randomized-trial-of-oral-and-transdermal-rivastigmine-for-postural-instability-in-parkinson-disease-dementia
#11
Jaime McDonald, Emmanuelle Pourcher, Alexandra Nadeau, Philippe Corbeil
OBJECTIVES: The objective of this study was to compare the efficacy and safety of oral and transdermal rivastigmine for postural instability in patients with Parkinson disease dementia (PDD) who were candidates for a cholinesterase inhibitor. The primary outcome was the change in mean velocity of the center of pressure (CoP) after 6 months. Secondary outcomes included structural parameters of dynamic posturography, clinical rating scales, and adverse events requiring dose reduction. METHODS: Patients with PDD were randomized in a 1:1 ratio to oral or transdermal rivastigmine with target doses of 6 mg twice daily and 9...
March 13, 2018: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/29508456/autonomic-dysfunction-in-genetic-forms-of-synucleinopathies
#12
REVIEW
Viorica Chelban, Ekawat Vichayanrat, Lucia Schottlaende, Valeria Iodice, Henry Houlden
The discovery of genetic links between alpha-synuclein and PD has opened unprecedented opportunities for research into a new group of diseases, now collectively known as synucleinopathies. Autonomic dysfunction, including cardiac sympathetic denervation, has been reported in familial forms of synucleinopathies that have Lewy bodies at the core of their pathogenesis. SNCA mutations and multiplications, LRRK2 disease with Lewy bodies as well as other common, sporadic forms of idiopathic PD, MSA, pure autonomic failure, and dementia with Lewy bodies have all been associated with dysautonomia...
March 2018: Movement Disorders: Official Journal of the Movement Disorder Society
https://www.readbyqxmd.com/read/29507258/caring-for-carers-of-people-with-dementia-a-protocol-for-harnessing-innovation-through-deploying-leading-edge-technologies-to-enable-virtual-support-groups-and-services
#13
Lynne Parkinson, Annie Banbury, Anne Livingstone, Steven Gordon, Biplob Ray, Louise Byrne, Susan Nancarrow, Chris Doran, Margaret McAllister, Carrie Petersen, Sonja Pedell, Denise Wood
In rural Australia, knowledge and utilisation of support by informal carers is lacking. During the caregiving period, socioemotional support from family and friends plays an important role in sustaining caregiving activities. Post-care, these social networks facilitate adjustment to role change and dealing with grief. Developing and improving access to peer support to enable carers to effectively cope with the challenges of caring may positively influence their caring experience. The primary objective of this project is to examine the response of isolated rural carers for older people with dementia to a videoconference (VC) based peer support and information program...
2018: Studies in Health Technology and Informatics
https://www.readbyqxmd.com/read/29503154/deep-brain-stimulation-of-the-pedunculopontine-nucleus-for-treatment-of-gait-and-balance-disorder-in-progressive-supranuclear-palsy-effects-of-frequency-modulations-and-clinical-outcome
#14
Imke Galazky, Jörn Kaufmann, Stefan Lorenzl, Georg Ebersbach, Florin Gandor, Tino Zaehle, Sylke Specht, Sabine Stallforth, Uwe Sobieray, Edyta Wirkus, Franziska Casjens, Hans-Jochen Heinze, Andreas Kupsch, Jürgen Voges
BACKGROUND: The pedunculopontine nucleus has been suggested as a potential deep brain stimulation target for axial symptoms such as gait and balance impairment in idiopathic Parkinson's disease as well as atypical Parkinsonian disorders. METHODS: Seven consecutive patients with progressive supranuclear palsy received bilateral pedunculopontine nucleus deep brain stimulation. Inclusion criteria comprised of the clinical diagnosis of progressive supranuclear palsy, a levodopa-resistant gait and balance disorder, age <75 years, and absence of dementia or major psychiatric co-morbidities...
May 2018: Parkinsonism & related Disorders
https://www.readbyqxmd.com/read/29390032/depression-in-parkinson-s-disease-a-case-control-study
#15
Yu-Hsuan Wu, Yi-Huei Chen, Ming-Hong Chang, Ching-Heng Lin
BACKGROUND: To evaluate the association between Parkinson's disease (PD) prognosis and the patient's onset of depression. METHODS: A total of 353 patients with newly-diagnosed PD and a history of depression were enrolled. On the basis of the onset of depression before or after PD diagnosis, we divided participants into PD patients with pre- or post-diagnostic depression. Cox's regression analysis was used to detect risks between the onset of depression and outcomes (including death, accidental injury, dementia, and aspiration pneumonia)...
2018: PloS One
https://www.readbyqxmd.com/read/29314218/goal-orientated-cognitive-rehabilitation-for-dementias-associated-with-parkinson-s-disease-a-pilot-randomised-controlled-trial
#16
John V Hindle, Tamlyn J Watermeyer, Julie Roberts, Andrew Brand, Zoe Hoare, Anthony Martyr, Linda Clare
OBJECTIVE: To examine the appropriateness and feasibility of cognitive rehabilitation for people with dementias associated with Parkinson's in a pilot randomised controlled study. METHODS: This was a single-blind pilot randomised controlled trial of goal-oriented cognitive rehabilitation for dementias associated with Parkinson's. After goal setting, participants were randomised to cognitive rehabilitation (n = 10), relaxation therapy (n = 10), or treatment-as-usual (n = 9)...
May 2018: International Journal of Geriatric Psychiatry
https://www.readbyqxmd.com/read/29305061/a-refined-concept-%C3%AE-synuclein-dysregulation-disease
#17
REVIEW
Hideki Mochizuki, Chi-Jing Choong, Eliezer Masliah
α-synuclein (αSyn) still remains a mysterious protein even two decades after SNCA encoding it was identified as the first causative gene of familial Parkinson's disease (PD). Accumulation of αSyn causes α-synucleinopathies including PD, dementia with Lewy bodies (DLB) and multiple system atrophy (MSA). Recent advances in therapeutic approaches offer new antibody-, vaccine-, antisense-oligonucleotide- and small molecule-based options to reduce αSyn protein levels and aggregates in patient's brain. Gathering research information of other neurological disease particularly Alzheimer's disease, recent disappointment of an experimental amyloid plaques busting antibody in clinical trials underscores the difficulty of treating people who show even mild dementia as damage in their brain may already be too extensive...
January 2, 2018: Neurochemistry International
https://www.readbyqxmd.com/read/29228071/associations-between-tau-%C3%AE-amyloid-and-cognition-in-parkinson-disease
#18
Joseph R Winer, Anne Maass, Peter Pressman, Jordan Stiver, Daniel R Schonhaut, Suzanne L Baker, Joel Kramer, Gil D Rabinovici, William J Jagust
Importance: Multiple disease processes are associated with cognitive impairment in Parkinson disease (PD), including Lewy bodies, cerebrovascular disease, and Alzheimer disease. It remains unknown whether tau pathology relates to cognition in patients with PD without dementia. Objective: To compare tau aggregation in patients with PD who are cognitively normal (PD-CN), patients with PD with mild cognitive impairment (PD-MCI), and healthy control participants, and evaluate the relationships between β-amyloid (Aβ), tau, and cognition in patients with PD who did not have dementia...
February 1, 2018: JAMA Neurology
https://www.readbyqxmd.com/read/29223069/neuropsychological-and-clinical-heterogeneity-of-cognitive-impairment-in-patients-with-multiple-system-atrophy
#19
Lorena Broseghini Barcelos, Flávia Saad, Carla Giacominelli, Roberta Arb Saba, Patrícia Maria de Carvalho Aguiar, Sonia Maria Azevedo Silva, Vanderci Borges, Paulo Henrique Ferreira Bertolucci, Henrique Ballalai Ferraz
OBJECTIVE: We evaluated neuropsychological tests to compare cognitive impairment between two types of multiple system atrophy: predominant parkinsonism (MSA-P) and predominant cerebellar ataxia (MSA-C). PATIENTS AND METHODS: This cross-sectional study included 14 patients diagnosed with MSA: four with MSA-C and ten with MSA-P. Presence of motor symptoms was determined by using the Unified Rating MSA Scale (URMSAS). Non-motor symptoms were evaluated by the Short Form Health Survey (SF-36), Scales for Outcomes in Parkinson's disease Autonomic (SCOPA-AUT), Hospital Anxiety and Depression Scale (HADS), and Beck Depression Inventory (BDI)...
January 2018: Clinical Neurology and Neurosurgery
https://www.readbyqxmd.com/read/29168904/apoe-thought-disorder-and-spare-ad-predict-cognitive-decline-in-established-parkinson-s-disease
#20
Thomas F Tropea, Sharon X Xie, Jacqueline Rick, Lana M Chahine, Nabila Dahodwala, Jimit Doshi, Christos Davatzikos, Leslie M Shaw, Vivianna Van Deerlin, John Q Trojanowski, Daniel Weintraub, Alice S Chen-Plotkin
BACKGROUND: People with PD are at high risk of developing cognitive impairment and dementia. Cross-sectional studies have identified candidate biomarkers associated with cognitive decline. However, longitudinal studies on this topic are rarer, and few have investigated the use of biomarker panels encompassing multiple modalities. The objective of this study was to find baseline predictors of cognitive decline in longitudinally followed, nondemented Parkinson's disease patients. METHODS: We performed a prospective cohort study of 100 PD patients with a median disease duration of 6...
February 2018: Movement Disorders: Official Journal of the Movement Disorder Society
keyword
keyword
70763
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"